CpG island methylation profiling in human salivary gland adenoid cystic carcinoma

Cancer

Volumn 117, Issue 13, 2011, Pages 2898-2909

  Bell, Achim ^a   Bell, Diana ^b   Weber, Randal S ^b   El Naggar, Adel K ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

adenoid cystic carcinoma; CpG island methylation; epigenetics; methylated CpG island amplification and microarray; pyrosequencing

Indexed keywords

ATROGIN 1; GENE PRODUCT; GLUTATHIONE TRANSFERASE; PROTEIN AQPEP; PROTEIN BCL2L11; PROTEIN DOCK1; PROTEIN EPHX3; PROTEIN FBXO17; PROTEIN GSTM5; PROTEIN LOXL1; PROTEIN MTIH; PROTEIN PARVG; PROTEIN PHKG1; PROTEIN SLC35D3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EN1; TRANSCRIPTION FACTOR FOXE1; TRANSCRIPTION FACTOR FOXL1; TRANSCRIPTION FACTOR GBX2; TRANSCRIPTION FACTOR IRX3; TRANSCRIPTION FACTOR LBX2; TRANSCRIPTION FACTOR MEIS1; TRANSCRIPTION FACTOR NKX2 4; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR NR2F2; TRANSCRIPTION FACTOR PITX1; TRANSCRIPTION FACTOR POU3F3; TRANSCRIPTION FACTOR TBX4; TRANSCRIPTION FACTOR TRAP2C; UNCLASSIFIED DRUG;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; AQPEP GENE; ARTICLE; BCL2L11 GENE; CLIC6 GENE; CLINICAL ARTICLE; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; DNA SEQUENCE; DOCK1 GENE; EN1 GENE; EPHX3 GENE; EPIGENETICS; FBXO17 GENE; FEMALE; FNDC1 GENE; FOXE1 GENE; FOXL1 GENE; GBX2 GENE; GENE AMPLIFICATION; GENE FUNCTION; GENE IDENTIFICATION; GSTM5 GENE; HUMAN; HUMAN TISSUE; INSRR GENE; IRX3 GENE; LBX2 GENE; LOXL1 GENE; MALE; MEIS1 GENE; MICROARRAY ANALYSIS; MT1H GENE; NKX2 4 GENE; NKX2 5 GENE; NR2F2 GENE; PARVG GENE; PITX1 GENE; PNLIPRP1 GENE; POU3F3 GENE; PRIORITY JOURNAL; PYROSEQUENCING; RASAL GENE; S1PR5 GENE; SALIVARY GLAND CARCINOMA; SLC35D3 GENE; TBX4 GENE; TISSUE SECTION; TRAP2C GENE; VALIDATION STUDY; XRN2 GENE;

ADULT; AGED; BASE SEQUENCE; CARCINOMA, ADENOID CYSTIC; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SALIVARY GLAND NEOPLASMS; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION FACTORS;

EID: 79959622508     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25818     Document Type: Article

References (39)

1. Takai D, Jones PA., Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A. 2002; 99: 3740-3745. (Pubitemid 34252176)
2. Toyota M, Ho C, Ahuja N, et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res. 1999; 59: 2307-2312. (Pubitemid 29242273)
3. Weinmann AS, Yan PS, Oberley MJ, Huang TH, Farnham PJ., Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. Genes Dev. 2002; 16: 235-244. (Pubitemid 34075815)
4. Estecio MR, Yan PS, Ibrahim AE, et al. High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res. 2007; 17: 1529-1536. (Pubitemid 47529437)
5. DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet. 1996; 14: 457-460. (Pubitemid 26414590)
6. Weber M, Davies JJ, Wittig D, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet. 2005; 37: 853-862. (Pubitemid 41077111)
7. Mayor R, Casadome L, Azuara D, et al. Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a noninvasive biomarker of disease. Br J Cancer. 2009; 100: 1534-1539.
8. Wu X, Rauch TA, Zhong X, et al. CpG island hypermethylation in human astrocytomas. Cancer Res. 2010; 70: 2718-2727.
9. Lasa A, Carnicer MJ, Aventin A, et al. MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias. Leukemia. 2004; 18: 1231-1237. (Pubitemid 39023133)
10. Cottrell S, Jung K, Kristiansen G, et al. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol. 2007; 177: 1753-1758. (Pubitemid 46560648)
11. Venza I, Visalli M, Tripodo B, et al. FOXE1 is a target for aberrant methylation in cutaneous squamous cell carcinoma. Br J Dermatol. 2010; 162: 1093-1097.
12. Dunwell T, Hesson L, Rauch TA, et al. A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol Cancer. 2010; 9: 44.
13. Landa I, Ruiz-Llorente S, Montero-Conde C, et al. The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genet. 2009; 5: e1000637.
14. Myatt SS, Lam EW., The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007; 7: 847-859. (Pubitemid 350006253)
15. Perreault N, Katz JP, Sackett SD, Kaestner KH., Foxl1 controls the Wnt/beta-catenin pathway by modulating the expression of proteoglycans in the gut. J Biol Chem. 2001; 276: 43328-43333.
16. Mutai H, Nagashima R, Sugitani Y, Noda T, Fujii M, Matsunaga T., Expression of Pou3f3/Brn-1 and its genomic methylation in developing auditory epithelium. Dev Neurobiol. 2009; 69: 913-930.
17. Li B, Kuriyama S, Moreno M, Mayor R., The posteriorizing gene Gbx2 is a direct target of Wnt signalling and the earliest factor in neural crest induction. Development. 2009; 136: 3267-3278.
18. Glinsky GV, Berezovska O, Glinskii AB., Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005; 115: 1503-1521. (Pubitemid 40814659)
19. Tong WG, Wierda WG, Lin E, et al. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics. 2010; 5: 499-508.
20. Kelemen LE, Wang X, Fredericksen ZS, et al. Genetic variation in the chromosome 17q23 amplicon and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1864-1868.
21. Ji H, Ehrlich LI, Seita J, et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature. 2010; 467: 338-342.
22. Ochi H, Westerfield M., Lbx2 regulates formation of myofibrils. BMC Dev Biol. 2009; 9: 13.
23. Nakshatri H, Mendonca MS, Bhat-Nakshatri P, Patel NM, Goulet RJ Jr, Cornetta K., The orphan receptor COUP-TFII regulates G2/M progression of breast cancer cells by modulating the expression/activity of p21(WAF1/CIP1), cyclin D1, and cdk2. Biochem Biophys Res Commun. 2000; 270: 1144-1153. (Pubitemid 30444846)
24. Woodfield GW, Chen Y, Bair TB, Domann FE, Weigel RJ., Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells. Genes Chromosomes Cancer. 2010; 49: 948-962.
25. Liu DX, Lobie PE., Transcriptional activation of p53 by Pitx1. Cell Death Differ. 2007; 14: 1893-1907. (Pubitemid 350011665)
26. Logan M, Tabin CJ., Role of Pitx1 upstream of Tbx4 in specification of hindlimb identity. Science. 1999; 283: 1736-1739.
27. Bigagli E, Luceri C, Bernardini S, Dei A, Dolara P., Extremely low copper concentrations affect gene expression profiles of human prostate epithelial cell lines. Chem Biol Interact. 2010; 188: 214-219.
28. Wilson AJ, Chueh AC, Togel L, et al. Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res. 2010; 70: 609-620.
29. Han J, Goldstein LA, Hou W, Gastman BR, Rabinowich H., Regulation of mitochondrial apoptotic events by p53-mediated disruption of complexes between antiapoptotic Bcl-2 members and Bim. J Biol Chem. 2010; 285: 22473-22483.
30. Lowe ME., The triglyceride lipases of the pancreas. J Lipid Res. 2002; 43: 2007-2016.
31. Lu Y, Liu P, James M, et al. Genetic variants cis-regulating Xrn2 expression contribute to the risk of spontaneous lung tumor. Oncogene. 2010; 29: 1041-1049.
32. Peng DF, Razvi M, Chen H, et al. DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma. Gut. 2009; 58: 5-15.
33. Anderegg U, Breitschwerdt K, Kohler MJ, et al. MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF-beta and pro-inflammatory cytokines. Exp Dermatol. 2005; 14: 709-718. (Pubitemid 41150367)
34. Weber A, Huesken C, Bergmann E, Kiess W, Christiansen NM, Christiansen H., Coexpression of insulin receptor-related receptor and insulin-like growth factor 1 receptor correlates with enhanced apoptosis and dedifferentiation in human neuroblastomas. Clin Cancer Res. 2003; 9: 5683-5692. (Pubitemid 37499491)
35. Glenn KA, Nelson RF, Wen HM, Mallinger AJ, Paulson HL., Diversity in tissue expression, substrate binding, and SCF complex formation for a lectin family of ubiquitin ligases. J Biol Chem. 2008; 283: 12717-12729.
36. Winchester JS, Rouchka EC, Rowland NS, Rice NA., In Silico characterization of phosphorylase kinase: evidence for an alternate intronic polyadenylation site in PHKG1. Mol Genet Metab. 2007; 92: 234-242. (Pubitemid 47516704)
37. Premkumar L, Bobkov AA, Patel M, et al. Structural basis of membrane targeting by the Dock180 family of Rho family guanine exchange factors (Rho-GEFs). J Biol Chem. 2010; 285: 13211-13222.
38. Yoshimi R, Yamaji S, Suzuki A, et al. The gamma-parvin-integrin-linked kinase complex is critically involved in leukocyte-substrate interaction. J Immunol. 2006; 176: 3611-3624. (Pubitemid 43364009)
39. Durr ML, Mydlarz WK, Shao C, et al. Quantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumors. PLoS One. 2010; 5: e10828.